Exceptional Response to Olaparib and Pembrolizumab for Pancreatic Adenocarcinoma With Germline BRCA1 Mutation and High Tumor Mutation Burden: Case Report and Literature Review

Detalles Bibliográficos
Autores principales: Lundy, Joanne, McKay, Owen, Croagh, Daniel, Ganju, Vinod
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Wolters Kluwer Health 2022
Materias:
Case Reports
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8830512/
https://www.ncbi.nlm.nih.gov/pubmed/35085003
http://dx.doi.org/10.1200/PO.21.00437
_version_ 1784648288569393152
author Lundy, Joanne
McKay, Owen
Croagh, Daniel
Ganju, Vinod
author_facet Lundy, Joanne
McKay, Owen
Croagh, Daniel
Ganju, Vinod
author_sort Lundy, Joanne
collection PubMed
description
format Online
Article
Text
id pubmed-8830512
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Wolters Kluwer Health
record_format MEDLINE/PubMed
spelling pubmed-88305122022-02-11 Exceptional Response to Olaparib and Pembrolizumab for Pancreatic Adenocarcinoma With Germline BRCA1 Mutation and High Tumor Mutation Burden: Case Report and Literature Review Lundy, Joanne McKay, Owen Croagh, Daniel Ganju, Vinod JCO Precis Oncol Case Reports Wolters Kluwer Health 2022-01-27 /pmc/articles/PMC8830512/ /pubmed/35085003 http://dx.doi.org/10.1200/PO.21.00437 Text en © 2022 by American Society of Clinical Oncology https://creativecommons.org/licenses/by/4.0/Licensed under the Creative Commons Attribution 4.0 License: https://creativecommons.org/licenses/by/4.0/
spellingShingle Case Reports
Lundy, Joanne
McKay, Owen
Croagh, Daniel
Ganju, Vinod
Exceptional Response to Olaparib and Pembrolizumab for Pancreatic Adenocarcinoma With Germline BRCA1 Mutation and High Tumor Mutation Burden: Case Report and Literature Review
title Exceptional Response to Olaparib and Pembrolizumab for Pancreatic Adenocarcinoma With Germline BRCA1 Mutation and High Tumor Mutation Burden: Case Report and Literature Review
title_full Exceptional Response to Olaparib and Pembrolizumab for Pancreatic Adenocarcinoma With Germline BRCA1 Mutation and High Tumor Mutation Burden: Case Report and Literature Review
title_fullStr Exceptional Response to Olaparib and Pembrolizumab for Pancreatic Adenocarcinoma With Germline BRCA1 Mutation and High Tumor Mutation Burden: Case Report and Literature Review
title_full_unstemmed Exceptional Response to Olaparib and Pembrolizumab for Pancreatic Adenocarcinoma With Germline BRCA1 Mutation and High Tumor Mutation Burden: Case Report and Literature Review
title_short Exceptional Response to Olaparib and Pembrolizumab for Pancreatic Adenocarcinoma With Germline BRCA1 Mutation and High Tumor Mutation Burden: Case Report and Literature Review
title_sort exceptional response to olaparib and pembrolizumab for pancreatic adenocarcinoma with germline brca1 mutation and high tumor mutation burden: case report and literature review
topic Case Reports
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8830512/
https://www.ncbi.nlm.nih.gov/pubmed/35085003
http://dx.doi.org/10.1200/PO.21.00437
work_keys_str_mv AT lundyjoanne exceptionalresponsetoolaparibandpembrolizumabforpancreaticadenocarcinomawithgermlinebrca1mutationandhightumormutationburdencasereportandliteraturereview
AT mckayowen exceptionalresponsetoolaparibandpembrolizumabforpancreaticadenocarcinomawithgermlinebrca1mutationandhightumormutationburdencasereportandliteraturereview
AT croaghdaniel exceptionalresponsetoolaparibandpembrolizumabforpancreaticadenocarcinomawithgermlinebrca1mutationandhightumormutationburdencasereportandliteraturereview
AT ganjuvinod exceptionalresponsetoolaparibandpembrolizumabforpancreaticadenocarcinomawithgermlinebrca1mutationandhightumormutationburdencasereportandliteraturereview

Ejemplares similares